These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35469951)

  • 21. Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects.
    Jennewein MF; MacCamy AJ; Akins NR; Feng J; Homad LJ; Hurlburt NK; Seydoux E; Wan YH; Stuart AB; Edara VV; Floyd K; Vanderheiden A; Mascola JR; Doria-Rose N; Wang L; Yang ES; Chu HY; Torres JL; Ozorowski G; Ward AB; Whaley RE; Cohen KW; Pancera M; McElrath MJ; Englund JA; Finzi A; Suthar MS; McGuire AT; Stamatatos L
    Cell Rep; 2021 Jul; 36(2):109353. PubMed ID: 34237283
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
    Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
    Front Immunol; 2021; 12():747830. PubMed ID: 34858404
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.
    Piccoli L; Park YJ; Tortorici MA; Czudnochowski N; Walls AC; Beltramello M; Silacci-Fregni C; Pinto D; Rosen LE; Bowen JE; Acton OJ; Jaconi S; Guarino B; Minola A; Zatta F; Sprugasci N; Bassi J; Peter A; De Marco A; Nix JC; Mele F; Jovic S; Rodriguez BF; Gupta SV; Jin F; Piumatti G; Lo Presti G; Pellanda AF; Biggiogero M; Tarkowski M; Pizzuto MS; Cameroni E; Havenar-Daughton C; Smithey M; Hong D; Lepori V; Albanese E; Ceschi A; Bernasconi E; Elzi L; Ferrari P; Garzoni C; Riva A; Snell G; Sallusto F; Fink K; Virgin HW; Lanzavecchia A; Corti D; Veesler D
    Cell; 2020 Nov; 183(4):1024-1042.e21. PubMed ID: 32991844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
    Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape.
    Starr TN; Czudnochowski N; Liu Z; Zatta F; Park YJ; Addetia A; Pinto D; Beltramello M; Hernandez P; Greaney AJ; Marzi R; Glass WG; Zhang I; Dingens AS; Bowen JE; Tortorici MA; Walls AC; Wojcechowskyj JA; De Marco A; Rosen LE; Zhou J; Montiel-Ruiz M; Kaiser H; Dillen JR; Tucker H; Bassi J; Silacci-Fregni C; Housley MP; di Iulio J; Lombardo G; Agostini M; Sprugasci N; Culap K; Jaconi S; Meury M; Dellota E; Abdelnabi R; Foo SC; Cameroni E; Stumpf S; Croll TI; Nix JC; Havenar-Daughton C; Piccoli L; Benigni F; Neyts J; Telenti A; Lempp FA; Pizzuto MS; Chodera JD; Hebner CM; Virgin HW; Whelan SPJ; Veesler D; Corti D; Bloom JD; Snell G
    Nature; 2021 Sep; 597(7874):97-102. PubMed ID: 34261126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccine based on folded receptor binding domain-PreS fusion protein with potential to induce sterilizing immunity to SARS-CoV-2 variants.
    Gattinger P; Kratzer B; Tulaeva I; Niespodziana K; Ohradanova-Repic A; Gebetsberger L; Borochova K; Garner-Spitzer E; Trapin D; Hofer G; Keller W; Baumgartner I; Tancevski I; Khaitov M; Karaulov A; Stockinger H; Wiedermann U; Pickl WF; Valenta R
    Allergy; 2022 Aug; 77(8):2431-2445. PubMed ID: 35357709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plant-Produced Glycosylated and In Vivo Deglycosylated Receptor Binding Domain Proteins of SARS-CoV-2 Induce Potent Neutralizing Responses in Mice.
    Mamedov T; Yuksel D; Ilgın M; Gurbuzaslan I; Gulec B; Yetiskin H; Uygut MA; Islam Pavel ST; Ozdarendeli A; Mammadova G; Say D; Hasanova G
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of Potent and Durable Neutralizing Antibodies Against SARS-CoV-2 Using a Receptor Binding Domain-Based Immunogen.
    Srivastava V; Niu L; Phadke KS; Bellaire BH; Cho MW
    Front Immunol; 2021; 12():637982. PubMed ID: 33777030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antigenic Cross-Reactivity Between SARS-CoV-2 S1-RBD and Its Receptor ACE2.
    Lai YC; Cheng YW; Chao CH; Chang YY; Chen CD; Tsai WJ; Wang S; Lin YS; Chang CP; Chuang WJ; Chen LY; Wang YR; Chang SY; Huang W; Wang JR; Tseng CK; Lin CK; Chuang YC; Yeh TM
    Front Immunol; 2022; 13():868724. PubMed ID: 35603169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant.
    Graham C; Seow J; Huettner I; Khan H; Kouphou N; Acors S; Winstone H; Pickering S; Galao RP; Dupont L; Lista MJ; Jimenez-Guardeño JM; Laing AG; Wu Y; Joseph M; Muir L; van Gils MJ; Ng WM; Duyvesteyn HME; Zhao Y; Bowden TA; Shankar-Hari M; Rosa A; Cherepanov P; McCoy LE; Hayday AC; Neil SJD; Malim MH; Doores KJ
    Immunity; 2021 Jun; 54(6):1276-1289.e6. PubMed ID: 33836142
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanism of an RBM-targeted rabbit monoclonal antibody 9H1 neutralizing SARS-CoV-2.
    Chu X; Ding X; Yang Y; Lu Y; Li T; Gao Y; Zheng L; Xiao H; Yang T; Cheng H; Huang H; Liu Y; Lou Y; Wu C; Chen Y; Yang H; Ji X; Guo H
    Biochem Biophys Res Commun; 2023 Jun; 660():43-49. PubMed ID: 37062240
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a Platform for Producing Recombinant Protein Components of Epitope Vaccines for the Prevention of COVID-19.
    Karyagina AS; Gromov AV; Grunina TM; Lyaschuk AM; Grishin AV; Strukova NV; Generalova MS; Galushkina ZM; Soboleva LA; Dobrinina OY; Bolshakova TN; Subbotina ME; Romanovskaya-Romanko EA; Krasilnikov IV; Polyakov NB; Solovyev AI; Grumov DA; Zhukhovitsky VG; Ryabova EI; Prokofiev VV; Lunin VG
    Biochemistry (Mosc); 2021 Oct; 86(10):1275-1287. PubMed ID: 34903153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
    Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
    mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical study of a DNA vaccine targeting SARS-CoV-2.
    Hayashi H; Sun J; Yanagida Y; Otera T; Kubota-Koketsu R; Shioda T; Ono C; Matsuura Y; Arase H; Yoshida S; Nakamaru R; Ju N; Ide R; Tenma A; Kawabata S; Ehara T; Sakaguchi M; Tomioka H; Shimamura M; Okamoto S; Amaishi Y; Chono H; Mineno J; Komatsuno T; Saito Y; Rakugi H; Morishita R; Nakagami H
    Curr Res Transl Med; 2022 Sep; 70(4):103348. PubMed ID: 35489099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and αOX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity.
    Scaglione A; Opp S; Hurtado A; Lin Z; Pampeno C; Noval MG; Thannickal SA; Stapleford KA; Meruelo D
    Front Immunol; 2021; 12():719077. PubMed ID: 34394127
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.
    Cameroni E; Bowen JE; Rosen LE; Saliba C; Zepeda SK; Culap K; Pinto D; VanBlargan LA; De Marco A; di Iulio J; Zatta F; Kaiser H; Noack J; Farhat N; Czudnochowski N; Havenar-Daughton C; Sprouse KR; Dillen JR; Powell AE; Chen A; Maher C; Yin L; Sun D; Soriaga L; Bassi J; Silacci-Fregni C; Gustafsson C; Franko NM; Logue J; Iqbal NT; Mazzitelli I; Geffner J; Grifantini R; Chu H; Gori A; Riva A; Giannini O; Ceschi A; Ferrari P; Cippà PE; Franzetti-Pellanda A; Garzoni C; Halfmann PJ; Kawaoka Y; Hebner C; Purcell LA; Piccoli L; Pizzuto MS; Walls AC; Diamond MS; Telenti A; Virgin HW; Lanzavecchia A; Snell G; Veesler D; Corti D
    Nature; 2022 Feb; 602(7898):664-670. PubMed ID: 35016195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes.
    Fu D; Zhang G; Wang Y; Zhang Z; Hu H; Shen S; Wu J; Li B; Li X; Fang Y; Liu J; Wang Q; Zhou Y; Wang W; Li Y; Lu Z; Wang X; Nie C; Tian Y; Chen D; Wang Y; Zhou X; Wang Q; Yu F; Zhang C; Deng C; Zhou L; Guan G; Shao N; Lou Z; Deng F; Zhang H; Chen X; Wang M; Liu L; Rao Z; Guo Y
    PLoS Biol; 2021 May; 19(5):e3001209. PubMed ID: 33961621
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Isolation and Characterization of Mouse Monoclonal Antibodies That Neutralize SARS-CoV-2 and Its Variants of Concern Alpha, Beta, Gamma and Delta by Binding Conformational Epitopes of Glycosylated RBD With High Potency.
    Mariotti S; Capocefalo A; Chiantore MV; Iacobino A; Teloni R; De Angelis ML; Gallinaro A; Pirillo MF; Borghi M; Canitano A; Michelini Z; Baggieri M; Marchi A; Bucci P; McKay PF; Acchioni C; Sandini S; Sgarbanti M; Tosini F; Di Virgilio A; Venturi G; Marino F; Esposito V; Di Bonito P; Magurano F; Cara A; Negri D; Nisini R
    Front Immunol; 2021; 12():750386. PubMed ID: 34764961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A SARS-CoV-2 Spike Receptor Binding Motif Peptide Induces Anti-Spike Antibodies in Mice andIs Recognized by COVID-19 Patients.
    Pratesi F; Errante F; Pacini L; Peña-Moreno IC; Quiceno S; Carotenuto A; Balam S; Konaté D; Diakité MM; Arévalo-Herrera M; Kajava AV; Rovero P; Corradin G; Migliorini P; Papini AM; Herrera S
    Front Immunol; 2022; 13():879946. PubMed ID: 35693806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.